What drugs are in the Immunology bispecifics class?

56 active programs in the Immunology bispecifics class are tracked in this platform view (60 listed in all, with those that have no recent activity shown separately), including sonelokimab, tilrekimig, and lunsekimig. The heatmap maps every drug against the indications it is being developed for.

What conditions are Immunology bispecifics being developed for?

Immunology bispecifics are in clinical development across 65 indications, including Systemic Lupus Erythematosus, Hidradenitis Suppurativa, Rheumatoid Arthritis, Atopic Dermatitis, and Asthma.

How many Immunology bispecifics are in late-stage trials?

Of the 56 tracked assets in the Immunology bispecifics class, 5 are at Phase 3 or later, developed by 40 sponsors, across 162 mapped trials.

What are the upcoming Immunology bispecifics catalysts?

Near-term catalysts in this class include ompekimig (data readout, Oct '26); tibulizumab (data readout, Nov '26); lutikizumab (data readout, Dec '26). Dates combine estimated trial readouts and confirmed FDA decision dates.

Dashboards / Mechanism heatmaps

Page updated Oct 6, 2026 · using data updated on Nov 12, 2026

Immunology bispecifics — Platform Heatmap

Bispecific antibodies in immunology: dual cytokine blockers that hit two inflammatory pathways at once, and T-cell engagers repurposed to reset the immune system in autoimmune disease.

56 active programs

65 indications

162 trials

5 at Phase 3 or later

40 sponsors

Targets: CD3 · CD19 · BCMA · TSLP · CD20 · IL-13

Beta 40 programs of 50 20 indications of 65 94 programs mapped curated roster · no per-cell AI classification ⏰ 15 due ≤6 mo click any cell → asset tearsheet

At a glance

40 programs in this class span 20 indications (94 drug–indication pairs mapped). The most contested indication is Systemic Lupus Erythematosus (20 programs).

Forward catalysts next 18 months⏰ 15 due ≤6 mo

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Drug × Indication

Each cell = this program’s trials in that indication. Click for details. · showing top 40 of 50 programs × top 20 of 65 indications by program count — long tail omitted for width, not a data cap.

⏰ Due soon Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →

	Systemic Lupus Erythematosus	Rheumatoid Arthritis	Hidradenitis Suppurativa	Atopic Dermatitis	Asthma	Chronic Obstructive Pulmonary Dis…	Chronic Rhinosinusitis With Nasal…	Hidradenitis	Sweat Gland Diseases	Lupus Nephritis	Psoriatic Arthritis	Sjögren's Disease	Idiopathic Thrombocytopenic Purpu…	Ulcerative Colitis	Systemic Sclerosis	Myasthenia Gravis	Dermatitis	Primary Membranous Nephropathy	Autoimmune Hemolytic Anemia	Crohn Disease
sonelokimabMoonLake ImmunotherapeuticsIL-17A × IL-17F
tilrekimigPfizerIL-4 × IL-13 × TSLP
lunsekimigSanofiTSLP × IL-13
tibulizumabZura BioBAFF × IL-17A
lutikizumabAbbVieIL-1α × IL-1β
arumakimigNovartisIL-1β × IL-18
CM512Keymed BiosciencesTSLP × IL-13
blinatumomabAmgenCD19 × CD3
gamgertamigOuro MedicinesBCMA × CD3
brivekimigSanofiTNF × OX40L
velinotamigCullinan TherapeuticsBCMA × CD3
ABO2203Abogen BiosciencesCD19 × CD3
AK139AkesoIL-4Rα × ST2 (IL-33 recep…
galvokimigUCBIL-13 × IL-17A × IL-17F
cizutamigUCBBCMA × CD3
GSK5926371GSKCD19 × CD20 × CD3
YK012Excyte BiopharmaCD19 × CD3
IBI3002Innovent BiologicsIL-4Rα × TSLP
mosunetuzumabRocheCD20 × CD3
CLN-978Cullinan TherapeuticsCD19 × CD3
surovatamigAstraZenecaCD19 × CD3
ATG-201UCBCD19 × CD3
amulirafusp alfaImmuneOnco Biopharmaceutica…CD20 × CD47
ATI-052Aclaris TherapeuticsTSLP × IL-4Rα
HB0043Shanghai Huaota Biopharmace…IL-17A × IL-36R
QX031NQyuns TherapeuticsTSLP × IL-33
odronextamabRegeneronCD20 × CD3
vonsetamigRegeneronBCMA × CD3
CND261UCBCD20 × CD3
MK-1045Merck & Co.CD19 × CD3
PIT565NovartisCD19 × CD3 × CD2
F182112Shandong New Time Pharmaceu…BCMA × CD3
SAR448501SanofiCD20 × myeloid phagocytic…
ompekimigPfizerIL-4 × IL-13 × IL-33
PF-07261271Pfizer / RocheIL-12/IL-23 p40 × TL1A
NAV-240Navigator MedicinesOX40L × TNF
CDX-622Celldex TherapeuticsSCF (stem cell factor) × …
talquetamabJohnson & JohnsonGPRC5D × CD3
plamotamabXencorCD20 × CD3
KT501SanofiCD19 × BCMA × CD3

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

White-space indications — a single asset 40 found

Indications where only ONE asset in this family competes — uncrowded ground for a new entrant.

⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 1 mapped landscape

More assets in this family (7) — same mechanism, beyond the matrix top 40 by activity

Phase	Mechanism	Company	Readout	Trial
Phase 2 (registered, not yet recruiting)	QLS4131 — BCMA × GPRC5D × CD3	Qilu Pharmaceutical	⏰ 4Q26	NCT07001839
Phase 1	BBT001 — IL-4Rα × IL-31	Bambusa Therapeutics	4Q27	NCT07717905
Phase 1	KT502 — CD19 × CD3	Kali Therapeutics	4Q27	NCT07564154
Phase 1	CC312 — CD19 × CD3 × CD28	CytoCares	3Q27	NCT07177911
Phase 1	A-319 — CD19 × CD3	ITabMed	⏰ 4Q26	NCT06400537
Phase 1	HB2198 — CD19 × CD20	Hinge Bio	4Q27	NCT07491900
Phase 1	LBL-051 — BCMA × CD19 × CD3	Oblenio Bio

Active programs — indication not yet mapped (6) — in-scope assets whose trials we haven’t yet resolved to an indication column

Phase	Mechanism	Company	Readout	Trial
Phase 1	BBT002 — IL-4Rα × IL-5unclassified	Bambusa Therapeutics	4Q27	NCT07436949
Phase 1	HB0056 — TSLP × IL-11unclassified	Shanghai Huaota Biopharma…	2Q25	NCT06612970
Phase 1	XmAb412 — TL1A × IL-23p19unclassified	Xencor	⏰ 2Q27	NCT07713485
Phase 1	ZL-1503 — IL-13 × IL-31Rαunclassified	Zai Lab	⏰ 1Q27	NCT07658482
Phase 1	XmAb657 — CD19 × CD3unclassified	Xencor	4Q28	NCT07284797
Phase 1	HBM7020 — BCMA × CD3unclassified	Otsuka Pharmaceutical	4Q28	NCT07649265

Trials not yet mapped to an indication (1) — trials of in-grid assets whose condition isn’t an indication column yet — surfaced per trial so none are hidden

Phase	Mechanism	Company	Modality	Readout	Trial
Ph1	CDX-622 — SCF (stem cell factor) × TSLPunclassified	Celldex Therapeutics		2Q26	NCT06650761

Dual cytokine / receptor blockers

24 active programs, most advanced first.

Drug	Targets	Sponsor	Phase	Main indications	Trials
sonelokimab	IL-17A × IL-17F	MoonLake Immunotherapeutics	Filed sec.gov clinicaltrials.gov	Hidradenitis Suppurativa · Hidradenitis · Sweat Gland Diseases	11
CM512	TSLP × IL-13	Keymed Biosciences	Phase 3 (registered, not yet recruiting) biospace.com link.springer.com	Chronic Rhinosinusitis With Nasal Polyps · Atopic Dermatitis · Chronic Urticaria	9
lunsekimig	TSLP × IL-13	Sanofi	Phase 3 sanofi.com clinicaltrials.gov	Chronic Obstructive Pulmonary Disease · Asthma · Chronic Rhinosinusitis With Nasal Polyps	10
lutikizumab	IL-1α × IL-1β	AbbVie	Phase 3 jamanetwork.com clinicaltrials.gov	Hidradenitis Suppurativa · Atopic Dermatitis · Rheumatoid Arthritis	9
tilrekimig Trispecific	IL-4 × IL-13 × TSLP	Pfizer	Phase 3 cdn.pfizer.com pfizer.com	Atopic Dermatitis · Dermatitis · Eczematous Skin Diseases	10
AK139	IL-4Rα × ST2 (IL-33 receptor)	Akeso	Phase 2 akesobio.com clinicaltrials.gov	Asthma · Chronic Rhinosinusitis With Nasal Polyps · Moderate-to-Severe Atopic Dermatitis	4
arumakimig	IL-1β × IL-18	Novartis	Phase 2 doi.org clinicaltrials.gov	X-linked Lymphoproliferative Syndrome Type 2 (XLP-2) · Juvenile Arthritis · Arthralgia	8
brivekimig	TNF × OX40L	Sanofi	Phase 2 sanofi.com clinicaltrials.gov	Hidradenitis Suppurativa · Focal Segmental Glomerulosclerosis · Lipoid Nephrosis	6
galvokimig Trispecific	IL-13 × IL-17A × IL-17F	UCB	Phase 2 ucb.com doi.org	Atopic Dermatitis · Chronic Obstructive Pulmonary Disease · Chronic Bronchitis	5
HB0043	IL-17A × IL-36R	Shanghai Huaota Biopharmaceutical	Phase 2 ncbi.nlm.nih.gov clinicaltrials.gov	Acne Vulgaris · Hidradenitis Suppurativa	3
IBI3002	IL-4Rα × TSLP	Innovent Biologics	Phase 2 academic.oup.com prnewswire.com	Atopic Dermatitis · Asthma	5
NAV-240	OX40L × TNF	Navigator Medicines	Phase 2 businesswire.com globenewswire.com	Hidradenitis Suppurativa	3
ompekimig Trispecific	IL-4 × IL-13 × IL-33	Pfizer	Phase 2 cdn.pfizer.com cdn.pfizer.com	Atopic Dermatitis	3
PF-07261271	IL-12/IL-23 p40 × TL1A	Pfizer / Roche Genentech	Phase 2 cdn.pfizer.com assets.roche.com	Ulcerative Colitis	2
tibulizumab	BAFF × IL-17A	Zura Bio	Phase 2 investors.zurabio.com sec.gov	Hidradenitis Suppurativa · Dermatitis · Sweat Gland Diseases	5
ATI-052	TSLP × IL-4Rα	Aclaris Therapeutics	Phase 1 globenewswire.com sec.gov	Asthma · Atopic Dermatitis	0
BBT001	IL-4Rα × IL-31	Bambusa Therapeutics	Phase 1 prnewswire.com prnewswire.com	Chronic Urticaria	3
BBT002	IL-4Rα × IL-5	Bambusa Therapeutics	Phase 1 prnewswire.com clinicaltrials.gov		3
CDX-622	SCF (stem cell factor) × TSLP	Celldex Therapeutics	Phase 1 ir.celldex.com clinicaltrials.gov	Asthma	2
CLD-423	IL-23p19 × TL1A	Caldera Therapeutics	Phase 1 calderatx.com qyuns.net	Inflammatory Bowel Disease	0
HB0056	TSLP × IL-11	Shanghai Huaota Biopharmaceutical	Phase 1 clinicaltrials.gov		1
QX031N	TSLP × IL-33	Qyuns Therapeutics	Phase 1 qyuns.net assets.roche.com	Chronic Obstructive Pulmonary Disease · Asthma	0
XmAb412	TL1A × IL-23p19	Xencor	Phase 1 investors.xencor.com clinicaltrials.gov		1
ZL-1503	IL-13 × IL-31Rα	Zai Lab	Phase 1 sec.gov clinicaltrials.gov		2

T-cell engagers for autoimmune disease

29 active programs, most advanced first.

Drug	Targets	Sponsor	Phase	Main indications	Trials
blinatumomab Industry + investigator trials	CD19 × CD3	Amgen	Phase 2 clinicaltrials.gov clinicaltrials.gov	Systemic Lupus Erythematosus · Autoimmune Diseases of the Nervous System · Myasthenia Gravis	7
gamgertamig Industry + investigator trials	BCMA × CD3	Ouro Medicines Gilead acquisition announced 2026-03-23; closing not confirmed	Phase 2 clinicaltrials.gov clinicaltrials.gov	Idiopathic Thrombocytopenic Purpura · Autoimmune Hemolytic Anemia · Autoimmune Bullous Disease	6
mosunetuzumab	CD20 × CD3	Roche Genentech	Phase 2 clinicaltrials.gov clinicaltrials.gov	Systemic Lupus Erythematosus · Lupus Nephritis	2
QLS4131 Trispecific	BCMA × GPRC5D × CD3	Qilu Pharmaceutical	Phase 2 (registered, not yet recruiting) clinicaltrials.gov ashpublications.org	Systemic Lupus Erythematosus	1
surovatamig	CD19 × CD3	AstraZeneca	Phase 2 clinicaltrials.gov clinicaltrials.gov	Primary Membranous Nephropathy · Rheumatoid Arthritis · Systemic Lupus Erythematosus	2
teclistamab Investigator-initiated	BCMA × CD3	Johnson & Johnson Janssen	Phase 2 clinicaltrials.gov pubmed.ncbi.nlm.nih.gov	Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5	1
velinotamig	BCMA × CD3	Cullinan Therapeutics ex-Greater China	Phase 1/2 clinicaltrials.gov clinicaltrials.gov	Systemic Lupus Erythematosus · Idiopathic Thrombocytopenic Purpura · Blood Platelet Disorders	2
YK012 Industry + investigator trials	CD19 × CD3	Excyte Biopharma	Phase 1/2 clinicaltrials.gov clinicaltrials.gov	Systemic Lupus Erythematosus · Primary Membranous Nephropathy	4
A-319 Investigator-initiated	CD19 × CD3	ITabMed	Phase 1 clinicaltrials.gov clinicaltrials.gov	Systemic Lupus Erythematosus	1
ABO2203 mRNA-encodedInvestigator-initiated	CD19 × CD3	Abogen Biosciences	Phase 1 clinicaltrials.gov prnewswire.com	Lupus Nephritis · Thrombocytopenia · Rheumatoid Arthritis	0
ATG-201	CD19 × CD3	UCB worldwide exclusive license, 2026-03-04	Phase 1 clinicaltrials.gov prnewswire.com	Systemic Lupus Erythematosus · Systemic Sclerosis · Sjögren's Disease	1
CC312 TrispecificIndustry + investigator trials	CD19 × CD3 × CD28	CytoCares	Phase 1 clinicaltrials.gov clinicaltrials.gov	Systemic Lupus Erythematosus	1
cizutamig Industry + investigator trials	BCMA × CD3	UCB acquired Candid Therapeutics, closed 2026-06-17	Phase 1 clinicaltrials.gov clinicaltrials.gov	Rheumatoid Arthritis · Systemic Lupus Erythematosus · Myasthenia Gravis	5
CLN-978	CD19 × CD3	Cullinan Therapeutics	Phase 1 clinicaltrials.gov clinicaltrials.gov	Systemic Lupus Erythematosus · Sjögren's Disease · Rheumatoid Arthritis	3
CND261 Industry + investigator trials	CD20 × CD3	UCB via Candid; ex-China rights	Phase 1 clinicaltrials.gov clinicaltrials.gov	Rheumatoid Arthritis · Systemic Lupus Erythematosus	2
F182112 Industry + investigator trials	BCMA × CD3	Shandong New Time Pharmaceutical	Phase 1 clinicaltrials.gov clinicaltrials.gov	Autoimmune Hemolytic Anemia · Systemic Lupus Erythematosus	2
GSK5926371 Trispecific	CD19 × CD20 × CD3	GSK	Phase 1 clinicaltrials.gov	Systemic Lupus Erythematosus · Rheumatoid Arthritis · Myositis	1
HBM7020	BCMA × CD3	Otsuka Pharmaceutical ex-Greater China	Phase 1 clinicaltrials.gov		1
KT501 Trispecific	CD19 × BCMA × CD3	Sanofi worldwide exclusive license from Kali Therapeutics, 2026-03-23	Phase 1 clinicaltrials.gov kalitherapeutics.com	Rheumatoid Arthritis	1
KT502	CD19 × CD3	Kali Therapeutics	Phase 1 clinicaltrials.gov	Rheumatoid Arthritis	1
LBL-051 Trispecific	BCMA × CD19 × CD3	Oblenio Bio	Phase 1 biospace.com	refractory autoimmune diseases	0
linvoseltamab Allergy	BCMA × CD3	Regeneron	Phase 1 clinicaltrials.gov	Food Hypersensitivity	1
MK-1045	CD19 × CD3	Merck & Co. MSD	Phase 1 clinicaltrials.gov merck.com	Systemic Lupus Erythematosus · Rheumatoid Arthritis	1
odronextamab	CD20 × CD3	Regeneron	Phase 1 clinicaltrials.gov	Lupus Nephritis · Systemic Lupus Erythematosus	1
PIT565 Trispecific	CD19 × CD3 × CD2	Novartis	Phase 1 clinicaltrials.gov clinicaltrials.gov	Rheumatoid Arthritis · Systemic Lupus Erythematosus	2
plamotamab	CD20 × CD3	Xencor	Phase 1 clinicaltrials.gov	Rheumatoid Arthritis	1
vonsetamig	BCMA × CD3	Regeneron	Phase 1 clinicaltrials.gov clinicaltrials.gov	Lupus Nephritis · Systemic Lupus Erythematosus	1
XmAb657	CD19 × CD3	Xencor	Phase 1 clinicaltrials.gov acrabstracts.org		1
talquetamab Investigator-initiated	GPRC5D × CD3	Johnson & Johnson Janssen	Investigator-initiated study (phase not assigned) clinicaltrials.gov	Myasthenia Gravis	0

Other immune-cell depleters

3 active programs, most advanced first.

Drug	Targets	Sponsor	Phase	Main indications	Trials
amulirafusp alfa	CD20 × CD47	ImmuneOnco Biopharmaceuticals	Phase 2/3 (registered, not yet recruiting) clinicaltrials.gov clinicaltrials.gov	Immunoglobulin G4-Related Disease · Systemic Lupus Erythematosus · Neuromyelitis Optica	3
HB2198	CD19 × CD20	Hinge Bio	Phase 1 clinicaltrials.gov clinicaltrials.gov	Lupus Nephritis	2
SAR448501	CD20 × myeloid phagocytic receptor (Dectin-1 per Dren Bio)	Sanofi	Phase 1 clinicaltrials.gov clinicaltrials.gov	Systemic Lupus Erythematosus · Rheumatoid Arthritis	2

Discontinued

Programs whose sponsor stopped development since 2023, with the stated date and reason.

Drug	Targets	Sponsor	Status
rozibafusp alfa	BAFF × ICOSL	Amgen	discontinued (2023-07, Ph2b SLE stopped for futility at 6th interim analysis; not safety-related)
JNJ-95475939	IL-4Rα × IL-31	Johnson & Johnson	discontinued (2025-12, Ph2b DUPLEX-AD terminated after interim analysis met futility criteria); ClinicalTrials.gov NCT06881251 completion 2026-04-07
imvotamab	CD20 × CD3	IGM Biosciences	discontinued (2025-01, insufficient depth/consistency of B-cell depletion in Phase 1b RA and SLE)

No recent activity

Programs whose trials ended or went quiet without an announced decision. Their status is unknown, not necessarily stopped.

Drug	Targets	Sponsor	Status
donzakimig	IL-13 × IL-22	UCB	unclear (Ph1/2a AD completed; not listed on UCB pipeline page as of 2026-10-06; no active trials)

How this list was built

Programs were identified from company releases, SEC filings, ClinicalTrials.gov and published papers, and each has at least one primary source. A program is listed when it is a bispecific (or multispecific) biologic in clinical development for an immune-mediated disease. Trials are linked to a program only when a trial intervention carries the program's own name or code. For T-cell engagers and other immune-cell depleters, only trials in autoimmune or allergic disease are counted, not their cancer trials. Phase is the most advanced stage the program has reached. Programs registered only in China's own trial registry, and very early programs, may be missing.

Frequently asked

Common questions about the Immunology bispecifics landscape

What drugs are in the Immunology bispecifics class?: 56 active programs in the Immunology bispecifics class are tracked in this platform view (60 listed in all, with those that have no recent activity shown separately), including sonelokimab, tilrekimig, and lunsekimig. The heatmap maps every drug against the indications it is being developed for.
What conditions are Immunology bispecifics being developed for?: Immunology bispecifics are in clinical development across 65 indications, including Systemic Lupus Erythematosus, Hidradenitis Suppurativa, Rheumatoid Arthritis, Atopic Dermatitis, and Asthma.
How many Immunology bispecifics are in late-stage trials?: Of the 56 tracked assets in the Immunology bispecifics class, 5 are at Phase 3 or later, developed by 40 sponsors, across 162 mapped trials.
What are the upcoming Immunology bispecifics catalysts?: Near-term catalysts in this class include ompekimig (data readout, Oct '26); tibulizumab (data readout, Nov '26); lutikizumab (data readout, Dec '26). Dates combine estimated trial readouts and confirmed FDA decision dates.
How is the Immunology bispecifics platform compiled?: Programs were identified from company releases, SEC filings, ClinicalTrials.gov and published papers, and each has at least one primary source. A program is listed when it is a bispecific (or multispecific) biologic in clinical development for an immune-mediated disease. Trials are linked to a program only when a trial intervention carries the program's own name or code. For T-cell engagers and other immune-cell depleters, only trials in autoimmune or allergic disease are counted, not their cancer trials. Phase is the most advanced stage the program has reached. Programs registered only in China's own trial registry, and very early programs, may be missing. Each cell links to the underlying trial records.
Is the Immunology bispecifics heatmap free to use?: Yes — viewing and searching the Immunology bispecifics heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.

Data: ClinicalTrials.gov · Curated program roster · Trials registered 2008 onwards.